Healthcare / Pharmaceutical RetailersJohannesburg
$3212.00
-191.00 (-5.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $438.8M · quality 36.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$27.5B
P/E
28.2x
↑EV/EBITDA
859.0x
↑ROE
17.3%
↑Gross Margin
22.0%
↓Debt/Equity
1.18
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.4%
FCF CAGR
—
FCF margin
1.6%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42.83B · net income $978.9M · FCF $689.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42.83B | $42.83B | $39.17B | $36.28B | $32.66B |
| Net Income | $978.9M | $978.9M | $1.18B | $984.5M | $1.00B |
| EBITDA | $3.21B | $3.21B | $3.30B | $2.91B | $2.79B |
| EPS | — | — | 1.38 | 1.15 | 1.16 |
| Gross Margin | 22.0% | 22.0% | 22.5% | 22.6% | 23.2% |
| Operating Margin | -4.2% | -4.2% | -2.9% | -2.8% | -2.2% |
| Net Margin | 2.3% | 2.3% | 3.0% | 2.7% | 3.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.18 | 1.18 | 1.19 | 1.27 | 1.28 |
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $689.1M | $689.1M | $-497.4M | $438.8M | $-236.0M |
| Returns | |||||
| ROE | 17.3% | 17.3% | 22.6% | 22.0% | 25.6% |
| Valuation | |||||
| P/E | 28.18 | 28.18 | 2279.27 | 2809.94 | 2321.58 |
| EV/EBITDA | 858.99 | 858.99 | 817.03 | 951.17 | 834.50 |
| P/B | 487.15 | 487.15 | 515.34 | 618.43 | 595.58 |
| Growth & Yield | |||||
| Revenue Growth | 9.3% | 9.3% | 8.0% | 11.1% | — |
| EPS Growth | — | — | 19.9% | -1.4% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.4%
Start / end P/E
n/dx → n/dx
EPS bridge
1.38 → n/d
Residual
-4.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.